A Phase II study of AZD4877 (a novel anti-mitotic agent) in advanced bladder cancer

Study identifier:D2782C00010

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial Cancer

Medical condition

Bladder Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD4877

Sex

All

Actual Enrollment

54

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 May 2008
Primary Completion Date: 01 May 2009
Study Completion Date: 01 Dec 2009

Study design

Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria